36.28
-0.15(-0.41%)
Currency In USD
| Previous Close | 36.43 |
| Open | 35.81 |
| Day High | 36.63 |
| Day Low | 35.34 |
| 52-Week High | 40.16 |
| 52-Week Low | 13.37 |
| Volume | 486,890 |
| Average Volume | 697,671 |
| Market Cap | 1.31B |
| PE | -10.37 |
| EPS | -3.5 |
| Moving Average 50 Days | 34.42 |
| Moving Average 200 Days | 23.82 |
| Change | -0.15 |
If you invested $1000 in Dianthus Therapeutics, Inc. (DNTH) since IPO date, it would be worth $156.16 as of November 08, 2025 at a share price of $36.28. Whereas If you bought $1000 worth of Dianthus Therapeutics, Inc. (DNTH) shares 5 years ago, it would be worth $371.72 as of November 08, 2025 at a share price of $36.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Dianthus Therapeutics to Participate in Four Investor Conferences During November
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune dise
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
GlobeNewswire Inc.
Oct 29, 2025 7:30 PM GMT
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned to include QMG ≥10 screening c
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
GlobeNewswire Inc.
Oct 16, 2025 11:00 AM GMT
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Demonstrated superior inhibition of pDCs vs. li